Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LAB
Strong SellSinkerStandard BioTools Inc. · Healthcare · United States · $252M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Standard BioTools develops, manufactures, and markets innovative research tools for life science, including instruments, reagents, and software for single-cell analysis and genomics. Its proprietary microfluidics technology enables high-throughput, high-resolution biological analysis crucial for academic, clinical, and pharmaceutical research. The company is a key provider of advanced analytical platforms that facilitate breakthroughs in precision medicine and scientific discovery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 97.9M | 106.3M | 91.0M | 85.3M | -4.5% | 84.6M | 82.5M | 82.1M | -1.9% |
| EPS | -0.49 | -0.19 | -0.52 | -0.20 | — | -0.13 | -0.10 | -0.16 | — |
| Shares | 391.5M | 391.5M | 377.5M | 386.4M | -1.3% | 392.6M | — | — | — |
| Debt | 102.7M | 98.2M | 30.7M | 30.8M | -33.0% | 28.1M | — | — | — |
| Equity | -81.5M | -148.1M | 471.7M | 424.3M | -10.1% | — | — | — | — |
| Op CF | -89.4M | -43.3M | -143.5M | -74.3M | — | -80.3M | — | — | — |
| Inv CF | -88.1M | 20.2M | 363.2M | 27.4M | — | — | — | — | — |
| Fin CF | 230.8M | -6.8M | -102.6M | 0.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LAB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LAB | Standard BioTools Inc.(you) | $252M | 18 | Strong Sell |
| RXST | RxSight, Inc. | $293M | 19 | Strong Sell |
| TLSI | TriSalus Life Sciences, Inc. | $297M | 20 | Strong Sell |
| CV | CapsoVision, Inc. | $297M | 13 | Strong Sell |
| MOBI | Mobia Medical, Inc. | $378M | 15 | Strong Sell |
| PAIN.V | Vector Science and Therapeutics Corp. | $233M | 8 | Strong Sell |
| CATX | Perspective Therapeutics, Inc. | $355M | 12 | Strong Sell |
| APYX | Apyx Medical Corporation | $130M | 18 | Strong Sell |
| PACB | Pacific Biosciences of California, Inc. | $435M | 16 | Strong Sell |
| OWLT | Owlet, Inc. | $146M | 15 | Strong Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%